RemeGen developed disitamab vedotin, China's first domestic ADC.
Disitamab vedotin (RC48) in gastric and urothelial cancer; telitacicept (autoimmune).
Disitamab vedotin is a Chinese HER2 ADC approved for gastric and bladder cancer, now in global trials with Pfizer.